Development of antibodies for immunotherapy of Alzheimer's disease

Matsumoto, Sanae; Jin, Haifeng; Takeda, Kazuya; Hasegawa, Yukako T.; Motoi, Yumiko; Tabira, Takeshi

doi:10.5692/clinicalneurol.52.1168

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous pairwise meta‐analyses were done to evaluate the efficacy safety of all types of immunotherapeutic agents targeting A β . However, these studies were inconclusive because many therapies have not been directly compared so that the question of which immunotherapies would be preferred for the treatment of AD remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

Yang

et al. 2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

To review the optimality and safety of different anti‐Amyloid‐β(Aβ) immunotherapies for Alzheimer's disease (AD). Published randomized controlled trials were comprehensively reviewed from electronic databases (Cochrane library, Embase, Pubmed, and Google scholar). Pooled outcomes as mean difference or odds ratio values with 95% confidence interval were reported. The network estimates with confidence and predictive intervals for all pairwise relative effects was evaluated. Optimal intervention was ranked by benefit‐risk ratio based on the surface under the cumulative ranking curve. Eleven eligible RCTs from 9 literatures, including 5141 patients and 5 interventions were included. The quality of evidence was rated low in comparisons. For efficacy, in terms of Mini‐Mental State Examination, aducanumab and solanezumab are significantly effective than placebo. For safety, in terms of Amyloid‐Related Imaging Abnormalities (ARIA), bapineuzumab and aducanumab are significantly worse than placebo. There were no significant differences in outcomes of Alzheimer's disease Assessment Scale‐Cognitive subscale, Disability Assessment for Dementia, Adverse Events, and mortality. Given the clinical therapeutic effects of anti‐Aβ immunotherapies for AD, aducanumab and solanezumab improve the cognitive function, while aducanumab and bapineuzumab may increase the risks of ARIA.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

Yang

et al. 2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

show abstract

“…In a good agreement with this approach, the inhibition of microglia protected hippocampal neurogenesis and reversed cognitive deficits in a mouse model [18]. On this note, specific antibodies have been developed for immunotherapy of AD [19] as a promising direction to prevent this mental disorder.…”

Section: Introductionmentioning

confidence: 71%

Preventive Therapy of Mental Disorders

Lipina¹

2015

Drug Des

View full text Add to dashboard Cite

Development of antibodies for immunotherapy of Alzheimer's disease

Cited by 2 publications

References 10 publications

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

Preventive Therapy of Mental Disorders

Contact Info

Product

Resources

About